Merit Medical Systems, Inc.  

(Public, NASDAQ:MMSI)   Watch this stock  
Find more results for MMSI
+0.39 (1.55%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 25.10 - 26.28
52 week 11.61 - 26.42
Open 25.17
Vol / Avg. 607,959.00/354,453.00
Mkt cap 1.13B
P/E 44.04
Div/yield     -
EPS 0.58
Shares 44.03M
Beta 1.10
Inst. own 88%
Oct 21, 2015
Q3 2015 Merit Medical Systems Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 23, 2015
Q2 2015 Merit Medical Systems Inc Earnings Call - Webcast
Jul 23, 2015
Q2 2015 Merit Medical Systems Inc Earnings Release
May 21, 2015
Merit Medical Systems Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 3.99% 4.51%
Operating margin 6.72% 7.88%
EBITD margin - 15.15%
Return on average assets 2.79% 3.11%
Return on average equity 4.73% 5.46%
Employees 3,105 -
CDP Score - -


1600 W Merit Pkwy
SOUTH JORDAN, UT 84095-2416
United States - Map
+1-801-2531600 (Phone)
+1-801-2531652 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Merit Medical Systems, Inc. (Merit) is a designer, developer, manufacturer and marketer of medical devices used in an array of interventional and diagnostic procedures across the world. The Company operates in the diagnostic and interventional cardiology, interventional radiology, interventional gastroenterology, interventional pulmonology, thoracic surgery, interventional nephrology, vascular surgery, oncology, electrophysiology, cardiac rhythm management and pain management markets. It operates in segments: cardiovascular and endoscopy. Its cardiovascular segment comprises cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases, and includes the embolotherapeutic products. Its endoscopy segment comprises gastroenterology and pulmonology devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors.

Officers and directors

Fred P. Lampropoulos Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kent W. Stanger Chief Financial Officer, Secretary, Treasurer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ronald A. Frost Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Rashelle Perry Chief Legal Officer
Age: 49
Bio & Compensation  - Reuters
A. Scott Anderson Independent Director
Age: 68
Bio & Compensation  - Reuters
Richard W. Edelman Independent Director
Age: 74
Bio & Compensation  - Reuters
Nolan E. Karras Independent Director
Age: 70
Bio & Compensation  - Reuters
Franklin J. Miller Independent Director
Age: 74
Bio & Compensation  - Reuters
F Ann Millner Independent Director
Bio & Compensation  - Reuters